Webinar
Safe and effective therapy for neuropsychiatric disorders
This webinar is now on demand!
Fill the form below to receive webinar video link directly to your inbox.
About “Safe and effective therapy for neuropsychiatric disorders” webinar
Neuropsychiatric disorders remain among the highest unmet medical needs in human medicine. Despite significant research efforts, limited therapeutic innovation and safety concerns continue to slow progress. As a result, there is an urgent need for safer and more effective treatment options.
To address this challenge, Synendos is developing a first-in-class approach targeting the endocannabinoid system. Specifically, their Selective Endocannabinoid Re-uptake Inhibitors (SERIs) are designed to modulate endogenous cannabinoid signaling while aiming to improve both efficacy and safety.
During this webinar, Synendos will present the discovery and development pathway of SYT-510, their lead SERIs candidate. First, the session will cover its synthesis and selection for preclinical development. Next, speakers will provide an overview of the preclinical data that supported regulatory approval for first-in-human studies. Finally, the webinar will outline the clinical development strategy and long-term vision to advance safer therapies for neuropsychiatric disorders.
In this webinar you will learn about:
- The potential of the endocannabinoids system in treating neuropsychiatric disorders
- Novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs)
- Synendos pre-clinical & clinical development of SYT-510
Keywords
SERI; Mental Health; Neuroscience; Swiss Healthcare; Innovation; Clinical Development; Biotech; Drug Discovery.
Meet the speakers of the “Safe and effective therapy for neuropsychiatric disorders” webinar
Andrea Chicca – Co-founder & CEO, Synendos Therapeutics
Maria Pia Catalani – Director, Lead Discovery Services, Axxam
Dr Andrea Chicca is a co-founder and CEO of Synendos Therapeutics AG, with more than 15 years of professional experience in developing therapeutics for central nervous system (CNS) disorders.
He holds a PhD in Pharmacology, a Master of Advanced Studies (MAS) in Translational Medicine and Biomedical Entrepreneurship, and an Executive MBA.
Previously, he served as a Scientific Advisor at Chiesi Pharmaceuticals, where he gained experience across both preclinical and clinical drug development.
In addition, he has co-authored more than 50 scientific publications and made significant contributions to understanding endocannabinoid membrane transport mechanisms. His work also supported the development of first-in-class Selective Endocannabinoid Reuptake Inhibitors (SERIs).
Maria Pia Catalani is Director of the Lead Discovery Department at Axxam. She joined the company in November 2019 as Head of the Discovery Chemistry Group and, in 2022, became Head of the Hit Tailoring Solution Group.
Before joining Axxam, she gained extensive industry experience at Evotec and Aptuit in Verona, Italy. During this time, she worked across multiple therapeutic areas, including CNS, gastrointestinal, and inflammatory diseases. In addition, she served as Chemistry Leader on several drug discovery programs, spanning hit-to-lead (H2L) and lead optimization (LO).
Earlier in her career, Maria Pia began working as a Medicinal Chemist in 2005 at the PsyCEDD, GlaxoSmithKline Medicines Research Centre in Verona. There, she built strong expertise in medicinal chemistry, contributing to CNS projects from hit identification through candidate selection.
From an academic perspective, Maria Pia holds a Master’s degree in Medicinal Chemistry from the University of Pisa and a PhD in Chemical Sciences from the University of Florence. Moreover, she is a co-author and co-inventor of several scientific publications and patents.